Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis).

Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R

Bone1 Feb 2001Cited by 112 (Europe PMC)

PMID11182372DOI10.1016/s8756-3282(00)00430-0PepBankPUB-11182372

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, PTH had minimal effects on bone formation rates at the studied times.
In plain wordsIn monkeys, PTH had minimal effects on bone formation rates compared with ovariectomized vehicle controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedBone formation rate
Study
Macaca fascicularisn: not reported in source
Ovariectomized cynomolgus monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.0 or 5.0 microg/kg per day · 18 monthsAs given in this study (Macaca fascicularis).
Source sentences
Summary
Treatment with PTH had minimal effects on bone formation rates at the timepoints studied
4 context sentences(design, population, supporting numbers)
Summary · context
The current study focuses on these parameters in the assessment of long-term (12 and 18 months) parathyroid hormone (PTH) therapy and its withdrawal (6 months) in the ovariectomized cynomolgus monkey (Macaca fascicularis), a well-characterized model for bone changes associated with postmenopausal osteoporosis.
Summary · context
Recombinant human PTH(1-34) was administered daily to two groups for 18 months at 1.0 microg/kg per day (n = 19) and 5.0 microg/kg per day (n = 21).
Summary · context
To study the effects of PTH withdrawal, two groups were administered PTH(1-34) daily for 12 months at 1.0 microg/kg per day (n = 20) and 5.0 microg/kg per day (n = 20), followed by daily administration of vehicle for 6 months.
Summary · context
Sham-ovariectomized and ovariectomized (ovx) groups each received daily injections of vehicle for 18 months.
Report a problemFND-1118237201
02AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, PTH increased cancellous bone volume versus OVX controls at the reported skeletal sites and times.
In plain wordsIn monkeys, PTH increased cancellous bone volume compared with OVX controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCancellous bone volume
Study
Macaca fascicularisn: not reported in source
Ovariectomized cynomolgus monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.0 or 5.0 microg/kg per day · 18 monthsAs given in this study (Macaca fascicularis).
Source sentences
Summary
but markedly increased cancellous bone volume relative to ovx monkeys in iliac crest biopsies at 6 and 15 months, as well as in terminal specimens of lumbar vertebrae, femoral neck, and distal radius after 18 months.
4 context sentences(design, population, supporting numbers)
Summary · context
The current study focuses on these parameters in the assessment of long-term (12 and 18 months) parathyroid hormone (PTH) therapy and its withdrawal (6 months) in the ovariectomized cynomolgus monkey (Macaca fascicularis), a well-characterized model for bone changes associated with postmenopausal osteoporosis.
Summary · context
Recombinant human PTH(1-34) was administered daily to two groups for 18 months at 1.0 microg/kg per day (n = 19) and 5.0 microg/kg per day (n = 21).
Summary · context
To study the effects of PTH withdrawal, two groups were administered PTH(1-34) daily for 12 months at 1.0 microg/kg per day (n = 20) and 5.0 microg/kg per day (n = 20), followed by daily administration of vehicle for 6 months.
Summary · context
Sham-ovariectomized and ovariectomized (ovx) groups each received daily injections of vehicle for 18 months.
Report a problemFND-1118237202
03AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, PTH increased trabecular number at all studied sites versus OVX controls.
In plain wordsIn monkeys, PTH increased trabecular number compared with OVX controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular number
Study
Macaca fascicularisn: not reported in source
Ovariectomized cynomolgus monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.0 or 5.0 microg/kg per day · 18 monthsAs given in this study (Macaca fascicularis).
Source sentences
Summary
At all sites, PTH significantly improved trabecular architecture, as evidenced by increased trabecular number (Tb.N) and decreased trabecular separation (Tb.Sp), with no significant change in trabecular thickness (Tb.Th).
4 context sentences(design, population, supporting numbers)
Summary · context
The current study focuses on these parameters in the assessment of long-term (12 and 18 months) parathyroid hormone (PTH) therapy and its withdrawal (6 months) in the ovariectomized cynomolgus monkey (Macaca fascicularis), a well-characterized model for bone changes associated with postmenopausal osteoporosis.
Summary · context
Recombinant human PTH(1-34) was administered daily to two groups for 18 months at 1.0 microg/kg per day (n = 19) and 5.0 microg/kg per day (n = 21).
Summary · context
To study the effects of PTH withdrawal, two groups were administered PTH(1-34) daily for 12 months at 1.0 microg/kg per day (n = 20) and 5.0 microg/kg per day (n = 20), followed by daily administration of vehicle for 6 months.
Summary · context
Sham-ovariectomized and ovariectomized (ovx) groups each received daily injections of vehicle for 18 months.
Report a problemFND-1118237203
04AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, PTH decreased trabecular separation versus OVX controls.
In plain wordsIn monkeys, PTH reduced gaps between trabeculae compared with OVX controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTrabecular separation
Study
Macaca fascicularisn: not reported in source
Ovariectomized cynomolgus monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.0 or 5.0 microg/kg per day · 18 monthsAs given in this study (Macaca fascicularis).
Source sentences
Summary
At all sites, PTH significantly improved trabecular architecture, as evidenced by increased trabecular number (Tb.N) and decreased trabecular separation (Tb.Sp), with no significant change in trabecular thickness (Tb.Th).
4 context sentences(design, population, supporting numbers)
Summary · context
The current study focuses on these parameters in the assessment of long-term (12 and 18 months) parathyroid hormone (PTH) therapy and its withdrawal (6 months) in the ovariectomized cynomolgus monkey (Macaca fascicularis), a well-characterized model for bone changes associated with postmenopausal osteoporosis.
Summary · context
Recombinant human PTH(1-34) was administered daily to two groups for 18 months at 1.0 microg/kg per day (n = 19) and 5.0 microg/kg per day (n = 21).
Summary · context
To study the effects of PTH withdrawal, two groups were administered PTH(1-34) daily for 12 months at 1.0 microg/kg per day (n = 20) and 5.0 microg/kg per day (n = 20), followed by daily administration of vehicle for 6 months.
Summary · context
Sham-ovariectomized and ovariectomized (ovx) groups each received daily injections of vehicle for 18 months.
Report a problemFND-1118237204
05AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized monkeys, PTH did not significantly change trabecular thickness versus OVX controls.
In plain wordsIn monkeys, PTH did not significantly change trabecular thickness compared with OVX controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTrabecular thickness
Study
Macaca fascicularisn: not reported in source
Ovariectomized cynomolgus monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.0 or 5.0 microg/kg per day · 18 monthsAs given in this study (Macaca fascicularis).
Source sentences
Summary
At all sites, PTH significantly improved trabecular architecture, as evidenced by increased trabecular number (Tb.N) and decreased trabecular separation (Tb.Sp), with no significant change in trabecular thickness (Tb.Th).
4 context sentences(design, population, supporting numbers)
Summary · context
The current study focuses on these parameters in the assessment of long-term (12 and 18 months) parathyroid hormone (PTH) therapy and its withdrawal (6 months) in the ovariectomized cynomolgus monkey (Macaca fascicularis), a well-characterized model for bone changes associated with postmenopausal osteoporosis.
Summary · context
Recombinant human PTH(1-34) was administered daily to two groups for 18 months at 1.0 microg/kg per day (n = 19) and 5.0 microg/kg per day (n = 21).
Summary · context
To study the effects of PTH withdrawal, two groups were administered PTH(1-34) daily for 12 months at 1.0 microg/kg per day (n = 20) and 5.0 microg/kg per day (n = 20), followed by daily administration of vehicle for 6 months.
Summary · context
Sham-ovariectomized and ovariectomized (ovx) groups each received daily injections of vehicle for 18 months.
Report a problemFND-1118237205
06AnimalAnimal study (in vivo)Mechanism
In monkeys, qualitative observations showed trabecular tunneling in the iliac crest and vertebra during PTH treatment.
In plain wordsIn monkeys, researchers observed trabecular tunneling in the iliac crest and vertebra during PTH treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableTrabecular tunneling
Study
Macaca fascicularisn: not reported in source
Ovariectomized cynomolgus monkeys
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.0 or 5.0 microg/kg per day · 18 monthsAs given in this study (Macaca fascicularis).
Source sentences
Summary
The mechanism of these structural changes is suggested by qualitative observations of trabecular tunneling observed in the iliac crest and vertebra.
4 context sentences(design, population, supporting numbers)
Summary · context
The current study focuses on these parameters in the assessment of long-term (12 and 18 months) parathyroid hormone (PTH) therapy and its withdrawal (6 months) in the ovariectomized cynomolgus monkey (Macaca fascicularis), a well-characterized model for bone changes associated with postmenopausal osteoporosis.
Summary · context
Recombinant human PTH(1-34) was administered daily to two groups for 18 months at 1.0 microg/kg per day (n = 19) and 5.0 microg/kg per day (n = 21).
Summary · context
To study the effects of PTH withdrawal, two groups were administered PTH(1-34) daily for 12 months at 1.0 microg/kg per day (n = 20) and 5.0 microg/kg per day (n = 20), followed by daily administration of vehicle for 6 months.
Summary · context
Sham-ovariectomized and ovariectomized (ovx) groups each received daily injections of vehicle for 18 months.
Report a problemFND-1118237206
07AnimalAnimal study (in vivo)Efficacy outcome
In monkeys, increased cancellous bone volume persisted after PTH withdrawal at the iliac crest, vertebra, and femoral neck.
In plain wordsIn monkeys, higher bone volume persisted after PTH withdrawal compared with OVX controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCancellous bone volume after withdrawal
Study
Macaca fascicularisn: not reported in source
Ovariectomized cynomolgus monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.0 or 5.0 microg/kg per day · 12 months followed by 3-6 months withdrawalAs given in this study (Macaca fascicularis).
Source sentences
Summary
A significant positive effect on cancellous bone volume was still apparent after a 3-6 month withdrawal period following 12 months of PTH treatment in the iliac crest, vertebra, and femoral neck.
4 context sentences(design, population, supporting numbers)
Summary · context
The current study focuses on these parameters in the assessment of long-term (12 and 18 months) parathyroid hormone (PTH) therapy and its withdrawal (6 months) in the ovariectomized cynomolgus monkey (Macaca fascicularis), a well-characterized model for bone changes associated with postmenopausal osteoporosis.
Summary · context
Recombinant human PTH(1-34) was administered daily to two groups for 18 months at 1.0 microg/kg per day (n = 19) and 5.0 microg/kg per day (n = 21).
Summary · context
To study the effects of PTH withdrawal, two groups were administered PTH(1-34) daily for 12 months at 1.0 microg/kg per day (n = 20) and 5.0 microg/kg per day (n = 20), followed by daily administration of vehicle for 6 months.
Summary · context
Sham-ovariectomized and ovariectomized (ovx) groups each received daily injections of vehicle for 18 months.
Report a problemFND-1118237207
08AnimalAnimal study (in vivo)Efficacy outcome
In monkeys, increased trabecular number remained significant after PTH withdrawal at the three responsive sites.
In plain wordsIn monkeys, increased trabecular number persisted after PTH withdrawal compared with OVX controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular number after withdrawal
Study
Macaca fascicularisn: not reported in source
Ovariectomized cynomolgus monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.0 or 5.0 microg/kg per day · 12 months followed by withdrawalAs given in this study (Macaca fascicularis).
Source sentences
Summary
Corresponding increases in Tb.N and decreases in Tb.Sp also remained significant after PTH withdrawal at these three sites.
5 context sentences(design, population, supporting numbers)
Summary · context
A significant positive effect on cancellous bone volume was still apparent after a 3-6 month withdrawal period following 12 months of PTH treatment in the iliac crest, vertebra, and femoral neck.
Summary · context
The current study focuses on these parameters in the assessment of long-term (12 and 18 months) parathyroid hormone (PTH) therapy and its withdrawal (6 months) in the ovariectomized cynomolgus monkey (Macaca fascicularis), a well-characterized model for bone changes associated with postmenopausal osteoporosis.
Summary · context
Recombinant human PTH(1-34) was administered daily to two groups for 18 months at 1.0 microg/kg per day (n = 19) and 5.0 microg/kg per day (n = 21).
Summary · context
To study the effects of PTH withdrawal, two groups were administered PTH(1-34) daily for 12 months at 1.0 microg/kg per day (n = 20) and 5.0 microg/kg per day (n = 20), followed by daily administration of vehicle for 6 months.
Summary · context
Sham-ovariectomized and ovariectomized (ovx) groups each received daily injections of vehicle for 18 months.
Report a problemFND-1118237208
09AnimalAnimal study (in vivo)Efficacy outcome
In monkeys, reduced trabecular separation remained significant after PTH withdrawal at the three responsive sites.
In plain wordsIn monkeys, reduced trabecular separation persisted after PTH withdrawal compared with OVX controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTrabecular separation after withdrawal
Study
Macaca fascicularisn: not reported in source
Ovariectomized cynomolgus monkeys
Comparator
OVX vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.0 or 5.0 microg/kg per day · 12 months followed by withdrawalAs given in this study (Macaca fascicularis).
Source sentences
Summary
Corresponding increases in Tb.N and decreases in Tb.Sp also remained significant after PTH withdrawal at these three sites.
5 context sentences(design, population, supporting numbers)
Summary · context
A significant positive effect on cancellous bone volume was still apparent after a 3-6 month withdrawal period following 12 months of PTH treatment in the iliac crest, vertebra, and femoral neck.
Summary · context
The current study focuses on these parameters in the assessment of long-term (12 and 18 months) parathyroid hormone (PTH) therapy and its withdrawal (6 months) in the ovariectomized cynomolgus monkey (Macaca fascicularis), a well-characterized model for bone changes associated with postmenopausal osteoporosis.
Summary · context
Recombinant human PTH(1-34) was administered daily to two groups for 18 months at 1.0 microg/kg per day (n = 19) and 5.0 microg/kg per day (n = 21).
Summary · context
To study the effects of PTH withdrawal, two groups were administered PTH(1-34) daily for 12 months at 1.0 microg/kg per day (n = 20) and 5.0 microg/kg per day (n = 20), followed by daily administration of vehicle for 6 months.
Summary · context
Sham-ovariectomized and ovariectomized (ovx) groups each received daily injections of vehicle for 18 months.
Report a problemFND-1118237209
10AnimalAnimal study (in vivo)Efficacy outcome
In monkeys, the distal radius responded less to PTH treatment and withdrawal than other bones.
In plain wordsIn monkeys, the distal radius responded less to PTH treatment and withdrawal than other bones.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedDistal radius responsiveness
Study
Macaca fascicularisn: not reported in source
Ovariectomized cynomolgus monkeys
Comparator
Other studied bones
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.0 or 5.0 microg/kg per day · 18 monthsAs given in this study (Macaca fascicularis).
Source sentences
Summary
The distal radius was relatively insensitive to PTH treatment or its withdrawal, compared with the other bones.
4 context sentences(design, population, supporting numbers)
Summary · context
The current study focuses on these parameters in the assessment of long-term (12 and 18 months) parathyroid hormone (PTH) therapy and its withdrawal (6 months) in the ovariectomized cynomolgus monkey (Macaca fascicularis), a well-characterized model for bone changes associated with postmenopausal osteoporosis.
Summary · context
Recombinant human PTH(1-34) was administered daily to two groups for 18 months at 1.0 microg/kg per day (n = 19) and 5.0 microg/kg per day (n = 21).
Summary · context
To study the effects of PTH withdrawal, two groups were administered PTH(1-34) daily for 12 months at 1.0 microg/kg per day (n = 20) and 5.0 microg/kg per day (n = 20), followed by daily administration of vehicle for 6 months.
Summary · context
Sham-ovariectomized and ovariectomized (ovx) groups each received daily injections of vehicle for 18 months.
Report a problemFND-1118237210

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.